生物制药公司Axsome Therapeutics(AXSM)今日盘中股价大跌5.02%，尽管公司第二季度财报显示收入超出市场预期。
根据公司发布的财报，Axsome第二季度调整后每股亏损0.97美元，好于分析师平均预期的亏损1.10美元。公司季度收入达到1.5004亿美元，同比增长72.1%，超过分析师预期的1.3882亿美元。然而，公司本季度仍录得净亏损4797万美元。
尽管收入增长强劲，但投资者似乎对公司持续亏损感到担忧。此外，分析师在过去三个月下调了公司的盈利预期，这可能也影响了投资者情绪。值得注意的是，尽管短期股价承压，华尔街分析师仍普遍看好该公司，给予"买入"评级，12个月目标价中位数为181.50美元，较当前股价有显著上行空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.